This is a working overview of deamidation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-13. Anything still debated is marked as such rather than presented as settled.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Mads Krogsgaard Thomsen (born December 27, 1960) is a Danish businessman who is the CEO of the Novo Nordisk Foundation and former executive vice president of research & development (R&D), head of R&D and chief scientific officer at the pharmaceutical company Novo Nordisk.
1995: British geomorphologist Marjorie Sweeting published the first comprehensive Western account of China's karst, entitled Karst in China: its Geomorphology and Environment. 1995: Israeli-Canadian mathematical biologist Leah Keshet became the first female president of the international Society for Mathematical Biology. 1995: British geochemist Jane Plant became the first female deputy director of the British Geological Survey. 1995: Inspectors from the United Nations Special Commission discovered that Iraqi microbiologist Rihab Taha, nicknamed "Dr. Germ", had been overseeing a secret 10-year biological warfare development program in Iraq. 1996: American planetary scientist Margaret G. Kivelson led a team that discovered the first subsurface, saltwater ocean on an alien world, on the Jovian moon Europa. 1997: Lithuanian-Canadian primatologist Birutė Galdikas received the Tyler Prize for Environmental Achievement for her research and rehabilitation work with orangutans. Her work with orangutans, eventually spanning over 30 years, was later recognized in 2014 as one of the longest continuous scientific studies of wild animals in history. 1997: Chilean astronomer María Teresa Ruiz discovered Kelu 1, one of the first observed brown dwarfs. In recognition of her discovery, she became the first woman to receive the Chilean National Prize for Exact Sciences. 1998: Nurse Fannie Gaston-Johansson became the first African-American woman tenured full professor at Johns Hopkins University. Late 1990s: Ethiopian-American chemist Sossina M. Haile developed the first solid acid fuel cell.
== Production == In China, the primary site of production of glass noodles is the town of Zhangxing, in Zhaoyuan, Shandong province. Historically the noodles were shipped through the port of Longkou, and thus the noodles are known and marketed as Longkou fensi (simplified Chinese: 龙口粉丝; traditional Chinese: 龍口粉絲).
Squids do not have the longitudinal muscles that octopus do. Instead, they have a tunic. This tunic is made of layers of collagen and it surrounds the top and the bottom of the mantle. Because they are made of collagen and not muscle, the tunics are rigid bodies that are much stronger than the muscle counterparts. This provides the squids some advantages for jet propulsion swimming. The stiffness means that there is no necessary muscle flexing to keep the mantle the same size. In addition, tunics take up only 1% of the squid mantle's wall thickness, whereas the longitudinal muscle fibers take up to 20% of the mantle wall thickness in octopuses. Also because of the rigidity of the tunic, the radial muscles in squid can contract more forcefully. The mantle is not the only place where squids have collagen. Collagen fibers are located throughout the other muscle fibers in the mantle. These collagen fibers act as elastics and are sometimes named "collagen springs". As the name implies, these fibers act as springs. When the radial and circular muscles in the mantle contract, they reach a point where the contraction is no longer efficient to the forward motion of the creature. In such cases, the excess contraction is stored in the collagen which then efficiently begins or aids in the expansion of the mantle at the end of the jet. In some tests, the collagen has been shown to be able to begin raising mantle pressure up to 50ms before muscle activity is initiated.
In the mobilization stage, the stepparent can begin to step forward to address the family's process and structure. The tasks of this stage are to confront differences in each member's perception of the new family, as well as to influence one another before shaming or blaming begins to take action to reorganize the family structure. The goal here is to make joint decisions about new stepfamily rituals, rules, and roles. The focus in this stage is on the stepfamily's unique "middle ground" (i.e. the "areas of shared experience, shared values, and easy cooperative functioning created over time"), and on balancing this new middle ground with honoring of past and other relationships. The later stages consist of the contact and resolution stages. In the contact stage, the couple is working well together, the boundaries between households are clear, and stepparents have definite roles with stepchildren as "intimate outsiders." The task for this stage is in solidifying the stepparent's role, and in continuing the process of awareness. Finally, in the resolution stage, the stepfamily's identity has become secure. The family accepts itself for who it is, there is a strong sense of the stepfamily's middle ground, and children feel secure in both households. The task for this stage is to nourish the depth and maturity gained through this process, and to rework any issues that might arise at family "nodal events" (e.g., weddings, funerals, graduations, etc.).
Sources: en.wikipedia.org
Stimulates parietal cell maturation and fundal growth. Causes chief cells to secrete pepsinogen, the zymogen (inactive) form of the digestive enzyme pepsin. Increases antral muscle mobility and promotes stomach contractions. Strengthens antral contractions against the pylorus, and relaxes the pyloric sphincter, which increases the rate of gastric emptying. Plays a role in the relaxation of the ileocecal valve. Induces pancreatic secretions and gallbladder emptying. May impact lower esophageal sphincter (LES) tone, causing it to contract, - although pentagastrin, rather than endogenous gastrin, may be the cause. Gastrin contributes to the gastrocolic reflex.
=== Stability === "LSD," writes the chemist Alexander Shulgin, "is an unusually fragile molecule ... As a salt, in water, cold, and free from air and light exposure, it is stable indefinitely." LSD has two labile protons at the tertiary stereogenic C5 and C8 positions, rendering these centers prone to epimerisation. The C8 proton is more labile due to the electron-withdrawing carboxamide attachment, but the removal of the chiral proton at the C5 position (which was once also an alpha proton of the parent molecule tryptophan) is assisted by the inductively withdrawing nitrogen and pi electron delocalisation with the indole ring. LSD also has enamine-type reactivity because of the electron-donating effects of the indole ring. Because of this, chlorine destroys LSD molecules on contact; even though chlorinated tap water contains only a slight amount of chlorine, the small quantity of compound typical to an LSD solution will likely be eliminated when dissolved in tap water. The double bond between the 8-position and the aromatic ring, being conjugated with the indole ring, is susceptible to nucleophilic attacks by water or alcohol, especially in the presence of UV or other kinds of light. LSD often converts to lumi-LSD (10-hydroxy-9,10-dihydro-LSD), which is inactive in human beings. A controlled study was undertaken to determine the stability of LSD in pooled urine samples.
== Products and services == Therapeutic antibody discovery Cell-receptor monoclonal antibody development In vivo animal study-grade antibodies development Molecular modeling Antibody sequencing Anti-idiotype antibody production Anti-protein antibodies for pharmacokinetics studies Immunogenicity assays for reagents and controls Immunoassay development Ligand-binding assay analysis Drug potency assay analysis Cell bank storage Full technical and project management
==== Canada ==== In Canada, codeine is regulated under the Narcotic Control Regulations (NCR), which falls under the Controlled Drugs and Substances Act (CDSA). Regulations state the pharmacists may, without a prescription, sell low-dose codeine products (containing up to 8 mg of codeine per tablet or up to 20 mg per 30 ml in liquid preparation) if the preparation contains at least two additional medicinal ingredients other than a narcotic (S.36.1 NCR). In Canada tablets containing 8 mg of codeine combined with 15 mg of caffeine and 300 mg of acetaminophen are sold as T1s (Tylenol Number 1) without a prescription. A similar tablet called "A.C. & C." (which stands for Acetylsalicylic acid with Caffeine and Codeine) containing 325–375 mg of acetylsalicylic acid (Aspirin) instead of acetaminophen is also available without a prescription. Codeine combined with an antihistamine, and often caffeine, is sold under various trade names and is available without a prescription. These products are kept behind the counter and must be dispensed by a pharmacist who may limit quantities. Names of many codeine and dihydrocodeine products in Canada tend to follow the narcotic content number system (Tylenol With Codeine No. 1, 2, 3, 4 &c) mentioned below in the section on the United States; it came to be in its current form with the Pure Food and Drug Act of 1906. Controlled Drugs and Substances Act (S.C. 1996, c. 19) effective 28 July 2020. Codeine is now classified under Schedule 1, giving it a higher priority in the treatments of offenders of the law.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.